Patent · US Expired

Prostate specific fusion protein compositions

US6395278B1 · kind B1 · utility

37Cited by
3References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 13, 1999
Grant dateMay 28, 2002
Priority date
Expiry dateJul 13, 2019

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions and methods for the therapy and diagnosis of cancer, such as prostate cancer, are disclosed. Compositions may comprise one or more prostate tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a prostate tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as prostate cancer. Diagnostic methods based on detecting a prostate tumor protein, or mRNA encoding such a protein, in a sample are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.